Research Analysts Set Expectations for Oculis Q2 Earnings

Oculis Holding AG (NASDAQ:OCS - Free Report) - Stock analysts at HC Wainwright dropped their Q2 2025 EPS estimates for Oculis in a research note issued on Monday, May 12th. HC Wainwright analyst Y. Chen now forecasts that the company will post earnings of ($0.47) per share for the quarter, down from their prior estimate of ($0.41). HC Wainwright currently has a "Buy" rating and a $32.00 price objective on the stock. The consensus estimate for Oculis' current full-year earnings is ($2.09) per share. HC Wainwright also issued estimates for Oculis' Q3 2025 earnings at ($0.47) EPS, Q4 2025 earnings at ($0.47) EPS, FY2025 earnings at ($2.20) EPS and FY2026 earnings at ($1.69) EPS.

Several other brokerages have also recently weighed in on OCS. Robert W. Baird boosted their price objective on shares of Oculis from $37.00 to $41.00 and gave the stock an "outperform" rating in a research note on Thursday, March 13th. Chardan Capital boosted their price objective on shares of Oculis from $28.00 to $33.00 and gave the stock a "buy" rating in a research note on Friday, May 9th.

Oculis Stock Performance

NASDAQ OCS opened at $17.76 on Wednesday. The firm's fifty day moving average price is $17.99 and its two-hundred day moving average price is $18.40. The stock has a market cap of $775.44 million, a PE ratio of -9.20 and a beta of 0.27. Oculis has a fifty-two week low of $10.79 and a fifty-two week high of $23.08. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.02 and a current ratio of 4.02.

Oculis (NASDAQ:OCS - Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported ($0.77) earnings per share for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.26). The company had revenue of $0.32 million for the quarter, compared to the consensus estimate of $0.22 million. Oculis had a negative return on equity of 71.31% and a negative net margin of 8,043.28%.

Institutional Trading of Oculis

Several institutional investors have recently modified their holdings of OCS. SR One Capital Management LP bought a new stake in shares of Oculis in the first quarter worth $6,137,000. Aberdeen Group plc boosted its position in Oculis by 24.1% during the first quarter. Aberdeen Group plc now owns 1,253,119 shares of the company's stock valued at $23,847,000 after acquiring an additional 243,695 shares during the last quarter. abrdn plc boosted its position in Oculis by 23.0% during the fourth quarter. abrdn plc now owns 1,009,424 shares of the company's stock valued at $17,150,000 after acquiring an additional 188,871 shares during the last quarter. Citadel Advisors LLC bought a new stake in Oculis during the fourth quarter valued at $389,000. Finally, XTX Topco Ltd bought a new stake in Oculis during the fourth quarter valued at $225,000. Institutional investors own 22.30% of the company's stock.

Oculis Company Profile

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.